ArticleAntimicrobial agents and chemotherapy2006
Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.The Pediatric infectious disease journal · 2013Guideline
- Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2009Guideline
- Therapeutic Potential of Propolis and Royal Jelly in Encephalitozoon Intestinalis Infection: An in Vitro Study.Acta parasitologica · 2025Article
- Research Progress in Mutagenesis Techniques forMini reviews in medicinal chemistry · 2025Review
- Establishment and application of a loop-mediated isothermal amplification method based onFrontiers in veterinary science · 2025Article
- Screening of the Pandemic Response Box identifies anti-microsporidia compounds.PLoS neglected tropical diseases · 2023Article
- Laboratory Cultivation ofInsects · 2022Article
- A Perspective on the Molecular Identification, Classification, and Epidemiology of Enterocytozoon bieneusi of Animals.Experientia supplementum (2012) · 2022Article
- Peculiarities of meroterpenoids and their bioproduction.Applied microbiology and biotechnology · 2021Review
- Article
- Therapeutic targets for the treatment of microsporidiosis in humans.Expert opinion on therapeutic targets · 2018Review
- Molecular characterization of3 Biotech · 2018Article
- Case Report: Ocular Microsporidiosis: Case in a Patient Returning from India and Review of the Literature.The American journal of tropical medicine and hygiene · 2018Review
- Porphyrins inactivate Nosema spp. microsporidia.Scientific reports · 2018Article
- Microsporidia: Obligate Intracellular Pathogens Within the Fungal Kingdom.Microbiology spectrum · 2017Review
- Successful Treatment of DisseminatedOpen forum infectious diseases · 2016Article
- The Development of Genetic Modification Techniques in Intracellular Parasites and Potential Applications to Microsporidia.PLoS pathogens · 2015Review
- Parasitic diarrheal disease: drug development and targets.Frontiers in microbiology · 2015Review
- Pathology of Experimental Encephalitozoon cuniculi Infection in Immunocompetent and Immunosuppressed Mice in Iraq.Pathology research international · 2014Article
- Effect of three drugs against Encephalitozoon cuniculi infection in immunosuppressed mice.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Therapies for microsporidiosis in humans are limited, and fumagillin, which appears to be the most broadly effective antimicrosporidial drug, is considered to be moderately toxic. The purpose of this study was to apply an in vitro drug screening assay for Encephalitozoon intestinalis and Vittaforma corneae and an in vivo athymic mouse model of V. corneae infection to assess the efficacy of TNP-470 (a semisynthetic analogue of fumagillin), ovalicin, and eight ovalicin derivatives. TNP-470, ovalicin, and three of the ovalicin derivatives inhibited both E. intestinalis and V. corneae replication by more than 70% in vitro. Another three of the ovalicin derivatives inhibited one of the two microsporidian species by more than 70%. None of the treated athymic mice survived the V. corneae infection, but they did survive statistically significantly longer than the untreated controls after daily treatment with fumagillin administered at 5, 10, and 20 mg/kg of body weight subcutaneously (s.c.), TNP-470 administered at 20 mg/kg intraperitoneally (i.p.), or ovalicin administered at 5 mg/kg s.c. Of two ovalicin derivatives that were assessed in vivo, NSC 9665 given at 10 mg/kg i.p. daily also statistically significantly prolonged survival of the mice. No lesions associated with drug toxicity were observed in the kidneys or livers of uninfected mice treated with these drugs at the highest dose of 20 mg/kg daily. These results thus support continued studies to identify more effective fumagillin-related drugs for treating microsporidiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.